AZD-5069 | CXCR2 Antagonist | AmBeed-信号通路专用抑制剂

首页 / / / CXCR / AZD-5069

AZD-5069 {[allProObj[0].p_purity_real_show]}

货号：A912767

AZD 5069 is a selective and reversible antagonist of CXCR2 that can inhibit CXCL8 binding to CXCR2 with pIC50 of 9.1.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

AZD-5069 化学结构
CAS号：878385-84-3

AZD-5069 3D分子结构
CAS号：878385-84-3

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

AZD-5069 纯度/质量文件产品仅供科研

货号：A912767 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell, 2024, 101755. Ambeed. [ A399663 ]; • EMBO J., 2024. Ambeed. [ A295334 ]; • JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]; • JMC, 2024. Ambeed. [ A210558 , A1518164 ]; • Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]; 更多 >

CXCR 亚型比较

产品名称	CXCR1 ↓ ↑	CXCR2 ↓ ↑	CXCR4 ↓ ↑	纯度
Reparixin	✔			99%+
SB225002		+++ CXCR2, IC50: 22 nM		99%+
Plerixafor			++ CXCR4, IC50: 44 nM	99%
AMD 3465 6HBr			✔	98%
WZ811			++++ CXCR4, EC50: 0.3 nM	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

AZD-5069 生物活性

描述	AZD-5069 is a CXCR2 antagonist by blocking [125I]-IL-8 binding to human CXCR2 receptors and by inhibiting GROα-induced calcium flux in human neutrophils that are loaded with the fluo-3 dye^[1].
体外研究	AZD-5069 is a CXCR2 antagonist by blocking [125I]-IL-8 binding to human CXCR2 receptors and by inhibiting GROα-induced calcium flux in human neutrophils that are loaded with the fluo-3 dye^[1].

AZD-5069 动物研究

Dose	Mice: 100 mg/kg^[1] (i.p.) Cynomolgus monkey: 30 mg/kg - 525 mg/kg^[2] (p.o., BID)
Administration	i.p., p.o.

AZD-5069 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02499328	Advanced Solid Tumors & Metast... 展开 >>atic Squamous Cell Carcinoma of the Head and Neck 收起 <<	Phase 1 Phase 2	Recruiting	October 31, 2019	-
NCT01962935	Chronic Obstructive Pulmonary ... 展开 >>Disease (COPD). 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 <<
NCT01989520	Uncontrolled and Persistent As... 展开 >>thma 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 <<

AZD-5069 参考文献

[1]Norman P, et al. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin Ther Pat. 2013 Jan;23(1):113-7.

AZD-5069 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.10mL

0.42mL

0.21mL

10.49mL

2.10mL

1.05mL

20.99mL

4.20mL

2.10mL

AZD-5069 技术信息

CAS号	878385-84-3
分子式	C₁₈H₂₂F₂N₄O₅S₂
分子量	476.518

别名
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

溶解度

DMSO: 95 mg/mL(199.36 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02499328	Advanced Solid Tumors & Metast... 展开 >>atic Squamous Cell Carcinoma of the Head and Neck 收起 <<	Phase 1 Phase 2	Recruiting	October 31, 2019	-
NCT01962935	Chronic Obstructive Pulmonary ... 展开 >>Disease (COPD). 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 <<
NCT01989520	Uncontrolled and Persistent As... 展开 >>thma 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 <<
NCT02583477	Metastatic Pancreatic Ductal A... 展开 >>denocarcinoma 收起 <<	Phase 1 Phase 2	Completed	-	United States, New York ... 展开 >> Research Site Rochester, New York, United States, 14642 United Kingdom Research Site Cambridge, United Kingdom, CB2 0QQ Research Site Glasgow, United Kingdom, G12 0YN Research Site London, United Kingdom, SE1 9RY Research Site London, United Kingdom, W12 0NN Research Site Manchester, United Kingdom, M20 4BX Research Site Wirral, United Kingdom, CH63 4JY 收起 <<
NCT01255592	Bronchiectasis ... 展开 >> Lung Disease Respiratory Diseases 收起 <<	Phase 2	Completed	-	Czech Republic ... 展开 >> Research Site Ostrava, Czech Republic Research Site Prague, Czech Republic Poland Research Site Krakow, Poland Research Site Lodz, Poland Research Site Warszawa, Poland United Kingdom Research Site Hull, East Yorkshire, United Kingdom Research Site Leicester, Leicestershire, United Kingdom Research Site Birmingham, Wstmid, United Kingdom Research Site Belfast, United Kingdom Research Site Bristol, United Kingdom Research Site Cambridge, United Kingdom Research Site London, United Kingdom Research Site Newcastle-upon-tyne, United Kingdom Research Site Salford, United Kingdom Research Site Wolverhampton, United Kingdom 收起 <<
NCT01233232	-		Completed	-	-
NCT01255592	-		Completed	-	-
NCT01890148	Asthma	Phase 1	Completed	-	Germany ... 展开 >> Research Site Grosshansdorf, Germany 收起 <<
NCT01233232	Scientific Terminology Chronic... 展开 >> Obstructive Pulmonary Disease (COPD) Laymen Terminology Chronic Bronchitis and Emphysema 收起 <<	Phase 2	Completed	-	Bulgaria ... 展开 >> Research Site Sofia, Bulgaria Germany Research Site Berlin, Germany Research Site GROßHANSDORF, Germany Hungary Research Site Debrecen, Hungary Research Site Pécs, Hungary Research Site Szeged, Hungary Research Site Százhalombatta, Hungary Ukraine Research Site Kyiv, Ukraine 收起 <<
NCT01890148	-		Completed	-	-
NCT00953888	Healthy	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site Nottingham, United Kingdom 收起 <<
NCT01480739	Chemokine Receptor 2 (CXCR2) A... 展开 >>ntagonist 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> London, UK, United Kingdom 收起 <<
NCT01051505	Healthy	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site London Bridge, United Kingdom 收起 <<
NCT01100047	Healthy	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site Croydon, United Kingdom 收起 <<
NCT01704495	-		Completed	-	-
NCT01704495	Asthma	Phase 2	Completed	-	-
NCT01332903	Healthy	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 <<
NCT03177187	Metastatic Castration Resistan... 展开 >>t Prostate Cancer 收起 <<	Phase 1 Phase 2	Not yet recruiting	December 2020	-
NCT01735240	Asthma, Pharm... 展开 >>acokinetics, Cmax, Tmax, λz, AUC, Ketoconazole, Metabolite 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> London, United Kingdom 收起 <<
NCT01083238	Chronic Obstructive Pulmonary ... 展开 >>Disease 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 <<

AZD-5069 {[allProObj[0].p_purity_real_show]}

AZD-5069 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

AZD-5069 质控信息

AZD-5069 生物活性

AZD-5069 动物研究

AZD-5069 临床研究

AZD-5069 参考文献

AZD-5069 实验方案

AZD-5069 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

AZD-5069 {[allProObj[0].p_purity_real_show]}

AZD-5069 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

AZD-5069 质控信息

AZD-5069 生物活性

AZD-5069 动物研究

AZD-5069 临床研究

AZD-5069 参考文献

AZD-5069 实验方案

AZD-5069 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

AZD-5069 纯度/质量文件产品仅供科研